13F Pro Quality Score

23.0/100

Rank #2,739 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

12.6/100

Profitability

16.9/100

Balance Sheet

16.5/100

Earnings Quality

44.3/100

Free Cash Flow

22.0/100

Institutional Flow

3.6/100

Revenue Scale

33.3/100

Dilution Risk

44.5/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

ARAY Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ACCURAY INC (ARAY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARAY at 23.0/100 on a 32-signal composite quality model, placing it at rank #2,739 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (3.6) and revenue growth (12.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 44.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ACCURAY INC reports quarterly revenue of $100.9M, net income of $-1.9M, free cash flow of $2.0M. Top institutional holders of ARAY by reported 13-F value include TCW GROUP, Neuberger Berman Group, ARMISTICE CAPITAL, based on the most recent SEC filings. ARAY trades on the Nasdaq exchange and files with the SEC under CIK 1138723. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARAY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ACCURAY INC directly from SEC EDGAR. ACCURAY INC's 13F Pro composite quality score has ranged between 23 and 41 since 2021, currently 23.0 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Fun facts about ACCURAY INC

Quirks, history, and lore behind ARAY — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Sunnyvale, California.
  • 2
    The Numbers
    Annual revenue in the range of roughly $200 million — not a giant, but it operates in over 30 countries and its machines carry price tags that make hospitals sweat.
  • 3
    The History
    Founded in the early 2000s and spun out of technology developed at Stanford University, it brought a fresh approach to an existing but clunky field of cancer treatment.
  • 4
    The Secret
    Its flagship system delivers radiation therapy by tracking a tumor in real time and moving with it — so the beam follows the cancer, not a rigid plan made days earlier.
  • 5
    The Lore
    Its CyberKnife system is essentially a robotic radiosurgery platform that can zap tumors anywhere in the body with sub-millimeter precision — no scalpel required.
  • 6
    The Giveaway
    Two flagship products: the CyberKnife robotic radiosurgery system and the TomoTherapy platform — tools that make radiation oncologists feel like they're living in the future.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$100.9M

Net Income

Q2 2026

$-1.9M

Free Cash Flow

Q2 2026

$2.0M

ROIC

Q2 2026

11.6%

D/E Ratio

Q2 2026

3.58

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-12.3% YoY
$401.9MFY 2026
FY23 $447.6MFY24 $446.6MFY25 $458.5MFY26 $401.9M

Net Income

-2992.0% YoY
$-49.2MFY 2026
FY23 $-9.3MFY24 $-15.5MFY25 $-1.6MFY26 $-49.2M

Operating Income

-437.3% YoY
$-26.4MFY 2026
FY23 $2.4MFY24 $504.0KFY25 $7.8MFY26 $-26.4M

EPS (Diluted)

FY 2026
FY23 $-0.10FY24 $-0.16FY25 $-0.02FY26

Total Assets

-5.6% YoY
$443.7MFY 2026
FY23 $479.2MFY24 $468.6MFY25 $470.2MFY26 $443.7M

Total Debt

-7.8% YoY
$149.4MFY 2026
FY23 $188.7MFY24 $187.7MFY25 $162.0MFY26 $149.4M

Op. Cash Flow

-344.1% YoY
$-7.0MFY 2026
FY23 $15.5MFY24 $-11.9MFY25 $2.9MFY26 $-7.0M

Free Cash Flow

-809.5% YoY
$-12.8MFY 2026
FY23 $2.9MFY24 $-15.5MFY25 $-1.4MFY26 $-12.8M

Get alerted when ARAY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ACCURAY INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of ARAY

Companies Similar to ARAY

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IRIX

IRIDEX CORP

26
AI score
Very similar · 2 shared holders
ANGO

ANGIODYNAMICS INC

30
AI score
Similar quality profile · 3 shared holders
TMCI

TREACE MEDICAL CONCEPTS, INC.

20
AI score
Similar quality profile · 3 shared holders
INGN

Inogen Inc

33
AI score
Similar quality profile · 3 shared holders
NEOG

NEOGEN CORP

42
AI score
Similar quality profile · 2 shared holders
ANIK

Anika Therapeutics, Inc.

32
AI score
Similar quality profile · 2 shared holders
ACNT

ASCENT INDUSTRIES CO.

17
AI score
Similar quality profile · 1 shared holders
OFIX

Orthofix Medical Inc.

35
AI score
Similar quality profile · 4 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put ARAY on your watchlist

Track score changes the day ACCURAY INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is ARAY a good stock to buy?

13F Pro's AI-powered analysis of ACCURAY INC (ARAY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARAY are available on the ARAY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ARAY is classified as a small company.

Which hedge funds own ARAY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARAY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ACCURAY INC's investment landscape.